Archive | Next Phase Archive RSS feed for this section

Digital RESI June Leading the Way in Digital Partnering – RESI Video Partnering Actually Works!

18 Jun

By Karen Deyo, Senior Investor Research Analyst, LSN

LSN continues to hold all-virtual RESI events, and each Digital RESI event surpasses the one before. At last week’s Digital RESI June Conference, we saw a record number of meetings taking place, with 2000+ meetings scheduled over three days across the globe. RESI logged over 800 hours of video conversations, as RESI attendees fit months of continuous meetings into a raucous three days of interactive dialogue. Digital RESI continues to provide a venue, albeit virtual, for investors and companies to connect, meet, maintain or transact business relationships. As with all RESI conferences, the 1:1 ratio of companies to investors promotes a lot of interaction, and, as the graph below shows, almost 80% of the meetings that took place were between companies and investors who were a fit for them. RESI continues to have a global reach, with people from all over the world connecting and participating in meetings, as demonstrated by the images below, depicting the partnering website traffic at different times.

Investors Are Doing Business As Usual

As many investors stressed in the panels recorded for RESI, they are still open for business, and RESI will continue to hold digital events to facilitate advancing relationships. Make sure to register for our upcoming 2-Day Dedicated Partnering Event, taking place July 27-28th, and our next Digital RESI, taking place Sept. 14-16th!

June 9th, 2020, at 3:00 a.m. Est

June 9th, 2020, at 9:00 a.m. Est

Digital RESI Featured “Live Panels”—It Worked!

11 Jun

By Karen Deyo, Senior Investor Research Analyst, LSN

In addition to the valuable prerecorded content available on the Digital RESI June Live Agenda (Click here will be available one month), this week’s conference featured live sessions.  The live sessions generated some buzz – including the Early Stage Therapeutics panel, with five investors discussing their investment mandates and how their own investment process works. The compelling dialog zeroed in on their current radar screen, what they look for, what’s hot and what’s not, as well as how the landscape has changed in the last few months. Here are a few highlights of their discussion.

Moderated by Brent Ahrens, General Partner of Canaan Partners, the panelists were:

  • Anjan Aralihalli, Venture Partner of CTI Life Sciences Fund
  • Shaan Gandhi, Principal of Northpond Ventures
  • Peter Neubeck, Partner, Head of Germany of Kurma Partners
  • Shobha Parthasarathi, VP, External Innovation & New Ventures of Xontogeny

The investor panelists all mentioned that while oncology is a hot area, it is also an oversaturated indication. Nevertheless, all panelists admitted that they are still interested in oncology companies, but may be tailoring their preferences away from certain types of treatment, including avoiding immuno-oncology therapies that are not completely novel, and combo therapies. In addition, the panel stressed the importance of data at the early stages of therapeutic development, as this is a startup’s primary way to showcase their value.

While agreeing that the landscape has changed in recent months, all of the panelists agreed that investors are still open for business. However, they cautioned that the investment pool has shrunk, as investors save more to help increase the runway of their portfolio companies. Many of the investors have noticed a decrease in valuations as well, in addition to a large number of companies that have quickly pivoted into the Covid space.

As a final piece of advice, the investors urged companies to do their research before reaching out to an investor, and to be thoughtful and detailed in their outreach message. While companies should not write messages that are extremely long and detailed, as the panelists mentioned the sheer volume of messages they receive at conferences such as RESI, it should be more than ‘check out my cool company.’ Also important is the need to keep track of previous communication – if you met with an investor previously, make sure to reference that! These small details are important to avoid leaving a lasting negative impression.

Click here to watch the full panel!

RESI: A New Era of Digital Conferences- SAVE THESE DATES!

11 Jun

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Digital RESI June was huge success, with 800+ global attendees, 72 continuous hours, and 2000+ partnering meetings. The RESI partnering system will stay open for another week, and all content on the “live” agenda will be available for another month; make sure to listen to what the who’s who of early stage investment have to say.

After this milestone of LSN’s 30th Global Conference, LSN is announcing the second Digital RESI 2-day Dedicated Partnering Event, taking place July 27th – 28th, as well as Digital RESI September, taking place September 14th – 16th, and the new, premier LSN event, the 4D Meets AI digital conference on September 17th – 18th.

The positive feedback from LSN’s global investor and entrepreneurial networks have encouraged LSN to pursue new alternatives to keep business alive and facilitate partnering in these challenging times. The successful metrics of the last three Digital RESI events have proven that the digital model can shift the conference paradigm. The whole LSN team thanks our global network of life science partners for supporting our efforts and helping us usher in a new era of digital conferences and partnering!




Congratulations to Our Digital RESI June Innovation Challenge Winners!

11 Jun

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claire

Our 3-day Digital RESI June conference came to an end yesterday, and we are very excited to announce the Top 3 Winners of the Innovation Challenge. Each participating finalist company had a dedicated page where you could view their virtual poster, short pitch, and other supplementary materials that the companies made available for viewing.

We will keep our Digital RESI June “live agenda” page open to the public for another month, so if you have not had the chance already, please visit Digital RESI June Live Agenda to see our virtual exhibit of some amazing technologies across therapeutics, medical devices, diagnostics, and digital health!

We would like to thank every Innovation Challenge company for their virtual presentations, and the hard work they put in to promote their technologies to RESI attendees. In all, we hope that all companies were able to make the most out of the digitally presented Innovation Challenge.

The Top 3 winners will be awarded with free tickets to future RESI conferences. Congratulations to the Top 3 winners, and thank you all for casting your votes!

First Place: Sen-Jam Pharmaceutical

Click Here to Check Out Sen-Jam Pharmaceutical’s Digital Poster

Sen-Jam Pharmaceutical is a therapeutics company focused on rapidly developing drugs to reduce pain and inflammation. We do this by combining approved FDA drugs that have never been combined before to create new formulations. Our 3 lead drugs are at varying stages of development for treatments including Viral Respiratory Infections (e.g. COVID-19), Opioid Withdrawal, and Alcohol Hangover prevention. We have 24+ Patents awarded and pending.

Jacqueline Iversen, RPh, MS, Head of Clinical Development, Sen-Jam Pharmaceutical | Jim Iversen, CEO/COO, Sen-Jam Pharmaceutical

Second Place: AyuVis Research

Click Here to Check Out AyuVis Research’s Digital Poster

AyuVis Research, Inc. is a late preclinical stage pharmaceutical company with novel small molecule compounds for treating complicated respiratory diseases like bronchopulmonary dysplasia (BPD), bacterial pneumonia, acute respiratory distress syndrome (ARDS) and systemic inflammatory syndrome (sepsis). A pre-IND meeting with the FDA is completed. The compounds modulate the innate immune system to control hyperinflammation and eliminate microbial pathogens. AyuVis’ new class of drug can also prevent and treat conditions like severe COVID-19 infection related lung injuries, ARDS, multiple organ failure and death, where traditional protocols have had limited results. Preclinical testing in animal models have demonstrated effective results for intravenous (IV), intranasal (IN), and intraperitoneal (IP) administration of the drug depending on the target disease and tissue being treated.

Suchismita Acharya, PhD, President and CEO & Management Team

Third Place: Oxidien Pharmaceuticals

Click Here to Check Out Oxidien Pharmaceuticals’ Digital Poster

Oxidien Pharmaceuticals is a clinical stage drug development company developing a treatment for enteric hyperoxaluria, a large unmet need in kidney disease. We have excellent safety and efficacy data using our proprietary, oral biologic with significant advantages over products in development. Enteric hyperoxaluria is a condition that affects 250,000 patients in the US alone. The company spun out from Captozyme, Inc., in 2019, before Captozyme was acquired by Arranta Bio in November of 2019. Oxidien is now presenting a de-risked opportunity for an investment partner to come in early as we get ready for a dose-finding Phase 2 study.

Helena Cowley, CEO, Oxidien Pharmaceuticals

Top Global Firms Selected: RESI Featured Company Pitch Session Finalists

4 Jun

By Karen Deyo, Senior Investor Research Analyst, LSN

LSN is pleased to announce the companies selected to participate in the Featured Company Pitch Session. Each company will be given a dedicated page that will highlight their pitch video, followed by a live Q&A session with a panel of relevant investors. Among these companies are groups sponsored by the National Institute on Aging, BioHealth Innovation, Life Science Queensland and Women in Bio. Check out the companies below, and make sure to view their pitches!

 

OncoSynergy Leveraging RESI to Help Fund Glioblastoma Trials

4 Jun

Anne-Marie Carbonell
President, Chief Medical Officer, CEO of OncoSynergy

Erich White
BD Manager of LSN

As part of Women In Bio’s continuing alliance with LSN and RESI, I spoke to one of their sponsored companies about their experiences at RESI. OncoSynergy is a finalist in the Digital RESI June Innovation Challenge. What follows is my interview with Anne-Marie Carbonell, President, Chief Medical Officer, CEO.

Erich White (EW): What is your tagline and elevator pitch to get the audience calibrated?

Anne-Marie Carbonell (AC): Tagline: A breakthrough approach to the treatment of cancer. Our lead therapeutic program, OS2966 was developed after decades of research relating to our target, CD29. Scientific advisor Rick Horowitz, PhD discovered CD29 while advisor Mina Bissell, PhD later demonstrated that CD29 plays a fundamental role in cross talk between tumor cells and the microenvironment. Co-Founder Shawn Carbonell, MD, PhD further demonstrated the critical role CD29 plays in metastasis, while Co-Founder Catherine Park, MD showed CD29 sensitizes cancer cells to radiation treatment. This body of work, continually validated by collaborators from world-class institutions, is the basis of our innovative approach. After orchestrating the successful FDA IND-approval, I am proud to lead the company’s novel therapeutic into Phase I clinical trials. Overall, our intent is to develop transformative multi-indication cancer drugs that change the standard of care and expedite these solutions to patients by leveraging biopharma/corporate partnerships and enhanced FDA programs.

EW: What funds have you raised, and what is your next fundraise?

AC: OncoSynergy is lucky to have the strong backing of our investors who are equally committed to our mission. Since 2011, we have raised approximately $25M including $1MM in NIH funding. (Developing a new class of therapy takes time!) We are currently raising a $10M round to fund our Phase 1 glioblastoma trial, grow our team and advance our acute leukemia program.

EW: How has LSN and RESI been helping to get you in front of investors? Please describe the coaching and what you have learned.

AC: This has been OncoSynergy’s first year participating in RESI conferences and I am definitely disappointed we didn’t participate before! The hands-on support of the LSN team led me to re-evaluate my outreach strategy as well as my pitch style. Based on this feedback, we developed a strategic vetting and outreach approach that, I am happy to say, has been very successful. I also realized the value in simplifying. Recording the 3-minute presentation for our RESI landing page was a huge help in that effort and has enabled me to modulate my presentation to the specific audience.

EW: Tell me how it has been going for you in terms of getting in front of investors

AC: We kicked off our fundraising campaign in March… enter COVID-19. That said, we have not been able to physically get in front of any investors. I am extremely grateful for video conferencing and that events like RESI decided to go digital. Because of this, we have had a steady stream of productive meetings. In fact, cutting out travel time has enabled me to take more meetings than usual.

EW: How big is your investor list and outreach? How did the fundraising dynamic change after RESI?

AC: Since March we have reached out to approximately 200 potential investors and the list continues to grow as we attend events like RESI. Not a day goes by that we are not following up, scheduling or initiating new outreach.

We built significant momentum around the April RESI event. Nothing like giving your pitch 20 times over 2 days to improve your presentation skills! Additionally, creating updated materials for our dedicated page was a great process. We revamped our executive summary, created a 1-pager and updated our pitch deck. When it was time to begin chasing and follow-up we were armed with great materials.

EW: How do you see the innovation Challenge and how are you approaching it?

AC: Having a dedicated page is also a great tool to help obtain meetings and prepare investors for meetings. If an investor has an idea of who we are and what we are about before our short 30-minute meeting, it dramatically increases the quality of the meeting.

EW: You also participated during the Digital RESI 2-Day Partnering Event last month. How many meetings were you able to secure?

AC: We held 20 meetings during the 2-day partnering event and also had a few others scheduled outside of the conference.

EW: How did you secure so many meetings? What did you do to get so many?

A: My team carefully vets each investor on the platform to ensure goals align and to discover what I call an “outreach angle.” Investors get bombarded with requests, so we need an angle to get them to pay attention! Whether it’s a synergy with a portfolio company, a geographic market of mutual interest or the delegate’s background, it helps to personalize. My team labels each investor P1 (P = priority), P2 or exclude. I send a well-crafted message to all P1 investors. Depending on meeting traffic I circle back to the P2 candidates. Then comes follow-up either via email, LinkedIn or the RESI platform. Overall, it’s a lot of work, but the process works to enable valuable strategic outreach.

EW: What helped you most to get those meetings?

AC: Carefully qualifying investors and persistent follow up. Everyone on our small team makes key contribution toward our business development efforts.

EW: What have you learned so far participating at RESI?

AC: RESI helped us refine our outreach process and materials as well as focus my pitch. The high volume of meetings is a great learning experience for any entrepreneur. I also learned how to get the most out of 30-minute meeting with an investor, including making sure I asked key questions at the beginning of the meeting to allow me to adapt my presentation to the audience.

EW: Any other comments?

AC: Fundraising is an extraordinary amount of work under normal circumstances. Although COVID-19 has brough about an additional layer of complexity and new challenges, I encourage all of my fellow entrepreneurs to stay positive! If your idea is great, the right investor is out there (and hopefully at RESI).

Nostopharma Using LSN and RESI Navigate A Seed Round

4 Jun

Katya Vert
CEO of Nostopharma

Erich White
BD Manager of LSN

Companies at all stages, from seed to series B, utilize RESI to increase the power of their fundraising efforts. I spoke to Katya Vert, CEO of Nostopharma to learn how RESI has helped her raise her seed round. Nostopharma is part of the delegation sponsored by Women In Bio, and a participant in the Digital RESI June Innovation Challenge.

Erich White (EW): What is your tagline and elevator pitch to get the audience calibrated?

Katya Vert (KV): Tagline: Treating rare abnormal bone growth disorders ; Pitch: Nostopharma is developing treatments that act on the molecular pathways triggered by physical trauma to the soft tissue around the joints causing abnormal bone formation. Abnormal bone growth affects up to 90% of patients with some fracture types, requiring costly surgery

EW: Tell me about your technology. Where it came from and current status?

KV: When Jelena Jeremic (now CSO) co-authored the “Nature” paper about the mechanism of abnormal bone growth in a genetic disease, I felt compelled to design a treatment. I came up with the plan to test known Hh pathway inhibitors together, in combination. Shortly, Jelena and I co-founded the company to implement this plan of repurposing proven technology from oncology field into the new field of orthopedic trauma and musculoskeletal health.

EW: What funds have you raised and what are you currently raising?

KV: The company is funded by  grants from Maryland Industrial Partnerships (MIPS). We also graduated from NSF I-Corps program where we received excellent support for our customer discovery process. Nostopharma is raising a seed round now to take the treatment that shows great promise in animal model testing into the IND stage and subsequent clinical trials.

EW: Enter RESI.  How has LSN and RESI been helping to get you in front of investors? Please describe the coaching and what you have learned.

KV: We have learned quite a bit – the coaching from LSN is very detailed. The first thing we learned is the standard set of templates that investors expect to see and what kind of information and messaging each template needs to contain. We now are mastering this “peel the onion” approach in our documents and see the results right away. Our story is clearer and more comprehensive than it has ever been.

EW: Tell me how it has been going for you in terms of getting in front of investors

KV: This is where LSN coaching is very helpful as well. We always knew that investors are very busy people and you need to be persistent. However, when it came to the second round of follow up, we usually felt the freeze – what do you write other than “I already sent you this message, can you look at it again now?” With LSN’s help, we are crafting differentiated messages and tactics on how to maximize the number of meetings with investors, during RESI and after it.

EW: How big is your investor list and outreach?  How did the fundraising dynamic change after RESI?

KV: We need to raise the seed round, so it is a daily and hourly work for us. June RESI will be our second conference, and participating there has definitely changed the dynamics, the scope and the pace. We now have our own database of investors, where we track the interactions and prioritize the strategic leads. LSN and RESI have brought a lot of structure in our search for funding.

EW: What do you believe is most important to you about the Innovation Challenge?

KV: The preparation. Being in the spotlight is only great if you are fully prepared. We are raising the bar for our messages and presentations and working hard with our advisors to improve.

EW: You also participated during the Digital RESI 2-Day Partnering Event last month. How many meetings were you able to secure?

KV: Just under 30

EW: How did you secure so many meetings? What did you do to get so many?

KV: I think that being a Featured Company really helped, since investors get to see your posterboard and pitch even before the meeting. The partnering platform is very easy to use and makes sending emails and doing the follow up really easy and streamlined. Once we wrote the introductory emails and follow up emails with the target messages it was so efficient to communicate with all the investors on the platform.

EW: What helped you most to get those meetings?

KV: I honestly think it was the intro email we sent. RESI had a webinar prior to the forum and shared some tips and proven tactics. We certainly liked the structured approach to messaging in emails. This is what worked right away, I think.

EW: How did those meetings go? Any follow-up yet?

KV: We certainly got a lot of the knowledgeable investors to the table. The feedback we got was tremendous. In cases we got to a “no”, we got there quickly, and participating investors provided the detailed explanation. Where investors were interested, we are following up on a few leads now.

EW: What have you learned so far participating at RESI?

KV: We learned so much: how to construct a pitch and what documents we should have in the package ready to go; we learned the “tiered approach” to effective follow up; we learned how to maximize the face time with any investor and what questions to ask them. I hope we learned how to get funded!

EW: Was this the first time you go in front of institutional investors?

KV: Yes

EW: Any other comments?

KV: I am impressed with the level of respect we receive as a company from both LSN and the investor community. RESI and LSN are a lot more than a platform – they walk us through the basics and even advanced techniques of interacting with investors for results. Webinars are hands-on and give you actionable advice. But we also found that every time we reach out to LSN with a question – someone responds very quickly! Investors on the platform are very involved as well in terms of providing feedback, follow up and letting us know their decision.

%d bloggers like this: